

Ligand-Controlled Switch in Diastereoselectivities: Catalytic Asymmetric Construction of Spirocyclic Pyrrolidine-azetidine/oxe(thie)tane Derivatives

Hua Deng,[†] Renmeng Jia,[†] Wu-Lin Yang, Xingxin Yu* and Wei-Ping Deng*

Shanghai Key Laboratory of New Drug Design & School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai, 200237, China

Table of Contents


General information	1
Table S1. Optimization of the reaction conditions	2
General procedure	3
Gram scale procedure	15
Synthetic transformations of the cycloadduct 3aa.....	15
Proposed transition states of the diastereodivergent asymmetric 1,3-dipolar cycloaddition	17
References.....	18
The absolute configuration determination of 3fa and 4fa.....	19
Chiral HPLC Chromatograms	22
¹H NMR and ¹³C NMR spectra.....	56

General information

¹H NMR spectrum were recorded on a Bruker AVANCE III 400 MHz spectrometer in CDCl₃. Chemical shifts were reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The spectrums are interpreted as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, brs = broad singlet, coupling constant(s) *J* are reported in Hz and relative integrations are reported. ¹³C NMR (100 MHz) spectrums were recorded on a Bruker AVANCE III 400 MHz spectrometer in CDCl₃. Chemical shifts were reported in ppm with the internal chloroform signal at 77.06 ppm as a standard. Optical rotations were measured on an AUTOPOL V. Diastereomeric ratios and enantiomeric excesses were determined from crude ¹H NMR spectroscopy interpretation or by analysis of HPLC traces, obtained by using chiralpak AD-H columns with *n*-hexane and *i*-propanol or ethanol as solvents. (Chiralpak AD-H columns were purchased from Daicel Chemical Industries, LTD.) Melting points were obtained in open capillary tubes using SGW X-4 micro melting point apparatus which were uncorrected. Mass spectrums were recorded on TOF mass Waters GCT Premier and Xevo G2 spectrometer. Solvents were dried and distilled following usual protocols. Commercially available materials purchased from Adamas-beta, TCI or Energy Chemical and were used as received.

Imino esters¹ and exocyclic alkenes: *tert*-butyl 3-(2-methoxy-2-oxoethylidene)azetidine-1-carboxylate (**2b**)² *tert*-butyl 3-(2-ethoxy-2-oxoethylidene)azetidine-1-carboxylate (**2c**)² and 2-(1-tosylazetidin-3-ylidene)acetonitrile (**2d**)² 2-(oxetan-3-ylidene)acetonitrile (**2e**)² methyl 2-(oxetan-3-ylidene)acetate (**2f**)² 2-(thietan-3-ylidene)acetonitrile (**2g**)³ ethyl 2-(thietan-3-ylidene)acetate (**2h**)², *tert*-butyl 4-(cyanomethylene)piperidine-1-carboxylate (**2i**)⁴ were prepared according to the literature procedure, *tert*-butyl 3-(cyanomethylene)azetidine-1-carboxylate (**2a**) were purchased from Bidepharm and were used as received.


Table S1. Optimization of the reaction conditions




Entry	Solvent	Base	Metal	Yield(%) ^b	exo/endo ^c	ee(%) ^c
1	CH ₂ Cl ₂	Cs ₂ CO ₃	CuBF ₄	96	8:1	97
2	THF	Cs ₂ CO ₃	CuBF ₄	94	7:1	97
3	Et ₂ O	Cs ₂ CO ₃	CuBF ₄	95	7:1	96
4	TBME	Cs ₂ CO ₃	CuBF ₄	96	7:1	96
5	(CH ₂ Cl) ₂	Cs ₂ CO ₃	CuBF ₄	97	6:1	97
6	toluene	Cs ₂ CO ₃	CuBF ₄	95	4:1	95
7	CH ₃ CN	Cs ₂ CO ₃	CuBF ₄	95	4:1	95
8	CHCl ₃	Cs ₂ CO ₃	CuBF ₄	96	8:1	96
9	Dioxane	Cs ₂ CO ₃	CuBF ₄	97	8:1	96
10	2-MeTHF	Cs ₂ CO ₃	CuBF ₄	89	8:1	95
11	CH ₃ OH	Cs ₂ CO ₃	CuBF ₄	trace	-	-
12	THF/CH ₃ OH	Cs ₂ CO ₃	CuBF ₄	trace	-	-
13 ^d	CH ₂ Cl ₂	DBU	CuBF ₄	96	4:1	97
14 ^d	CH ₂ Cl ₂	Et ₃ N	CuBF ₄	93	8:1	93
15 ^e	CH ₂ Cl ₂	K ₂ CO ₃	CuBF ₄	96	7:1	96
16 ^d	CH ₂ Cl ₂	LiHMDS	CuBF ₄	92	7:1	95
17 ^d	CH ₂ Cl ₂	DIPEA	CuBF ₄	trace	-	-
18 ^d	CH ₂ Cl ₂	TMG	CuBF ₄	84	4:1	95
19 ^d	CH ₂ Cl ₂	DABCO	CuBF ₄	60	8:1	97
20 ^d	CH ₂ Cl ₂	tBuOK	CuBF ₄	92	6:1	97
21 ^d	CH ₂ Cl ₂	DMAP	CuBF ₄	NR	-	-
22 ^e	CH ₂ Cl ₂	Na ₂ CO ₃	CuBF ₄	94	8:1	96
23 ^d	CH ₂ Cl ₂	NaOH	CuBF ₄	94	9:1	95
24 ^d	CH ₂ Cl ₂	KOH	CuBF ₄	94	8:1	96
25	CH ₂ Cl ₂	Cs ₂ CO ₃	CuPF ₆	70	4:1	94
26	CH ₂ Cl ₂	Cs ₂ CO ₃	Cu(OTf) ₂	93	9:1	96
27	CH ₂ Cl ₂	Cs ₂ CO ₃	CuOAc	86	4:1	95
28	CH ₂ Cl ₂	Cs ₂ CO ₃	AgSbF ₆	88	1.3:1	76/81
29	CH ₂ Cl ₂	Cs ₂ CO ₃	AgF	91	1.6:1	73/84
30	CH ₂ Cl ₂	Cs ₂ CO ₃	AgBF ₄	79	1.3:1	73/85
31	CH ₂ Cl ₂	Cs ₂ CO ₃	AgClO ₄ ·H ₂ O	NR	-	-
32	CH ₂ Cl ₂	Cs ₂ CO ₃	Ag ₂ CO ₃	94	1.3:1	73/77

^a Unless otherwise stated, the reactions were performed with **1a** (0.12 mmol), **2a** (0.10 mmol) in 1.0 mL of solvent, under an N₂ atmosphere at rt, 1 equiv of base was used, CuBF₄ = Cu(MeCN)₄BF₄, CuPF₆ = Cu(MeCN)₄PF₆, TMG = Tetramethylguanidine. ^b Isolated yield. ^c The ratio of *exo/endo* was determined by ¹H NMR spectroscopy or/and chiral HPLC analysis, and the ee was determined by chiral HPLC analysis. ^d 20 mol% of base was used. ^e 2 equiv of base was used.


General procedure




At a nitrogen atmosphere, $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (3.1 mg, 0.01 mmol) and **L6** (5.8 mg, 0.011 mmol) were dissolved in 2.0 mL dry CH_2Cl_2 , subsequently add 4 Å Ms (100 mg), and stirred at room temperature for about 1 h. Then, iminoester **1** (0.24 mmol) and Cs_2CO_3 (65.2 mg, 0.2 mmol) were added, the mixture was cooled to -20 °C and alkene **2** (0.2 mmol) was added. Once starting material was consumed (about 0.5-1 h, monitored by TLC), the mixture was concentrated and the residue was purified by column chromatography (petroleum ether/ethyl acetate 6:1 to 2:1) on silica gel to afford the corresponding product **3**.



2-(tert-Butyl) 5-methyl (5*S*,7*R*,8*R*)-7-(4-chlorophenyl)-8-cyano-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 98%; m.p.: 165–167 °C; $[\alpha]_D^{25} = +134.5$ (*c* 1.00, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.49 – 7.42 (m, 2H), 7.39 – 7.33 (m, 2H), 4.35 (d, *J* = 9.3 Hz, 1H), 4.29 (d, *J* = 9.1 Hz, 1H), 4.13 (s, 1H), 4.05 (d, *J* = 9.2 Hz, 1H), 3.94 (d, *J* = 9.7 Hz, 1H), 3.86 (d, *J* = 9.8 Hz, 1H), 3.83 (s, 3H), 3.22 (d, *J* = 9.3 Hz, 1H), 2.52 (brs, 1H), 1.45 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 172.4, 155.8, 137.5, 134.6, 129.2 (2C), 128.1 (2C), 116.9, 80.4, 66.2, 63.5, 58.2, 54.2, 52.7, 46.0, 45.3, 28.3 (3C). HRMS (ESI-TOF) calcd for $[\text{C}_{20}\text{H}_{24}\text{ClN}_3\text{O}_4+\text{H}]^+$: 406.1528, found: 406.1532; HPLC (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 10.40 min, 16.03 min.




2-(tert-Butyl) 5-ethyl (5*S*,7*R*,8*R*)-7-(4-chlorophenyl)-8-cyano-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 97%; m.p.: 169–171 °C; $[\alpha]_D^{25} = +141.3$ (*c* 1.00, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.46 (d, *J* = 8.5 Hz, 2H), 7.36 (d, *J* = 8.3 Hz, 2H), 4.52 (d, *J* = 7.1 Hz, 1H, minor), 4.41 – 4.23 (m, 4H), 4.17 (d, *J* = 8.9 Hz, 1H, minor), 4.13 – 4.03 (m, 2H), 3.97 (d, *J* = 9.4 Hz, 1H), 3.85 (d, *J* = 9.7 Hz, 1H), 3.48 (d, *J* = 7.1 Hz, 1H, minor), 3.21 (d, *J* = 9.1 Hz, 1H), 2.54 (s, 1H), 1.45 (s, 9H), 1.35 (t, *J* = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ (major + minor) 171.8, 171.1, 170.8, 155.7, 137.6, 134.5, 129.1 (2C), 129.0, 128.4, 128.0 (2C), 117.0, 80.3, 66.2, 63.5, 62.1, 61.9, 61.1, 60.4, 58.1, 54.4, 46.3, 46.1, 45.2, 45.0, 28.3 (3C), 21.0, 14.2. HRMS (ESI-TOF) calcd for $[\text{C}_{21}\text{H}_{26}\text{ClN}_3\text{O}_4+\text{H}]^+$: 420.1685, found: 420.1689; HPLC (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 10.15 min, 17.21 min.




2-*tert*-Butyl (5*S*,7*R*,8*R*)-7-(4-chlorophenyl)-8-cyano-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate

White solid, yield: 96%; m.p.: 174–176 °C; $[\alpha]_D^{25} = +174.2(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **1H NMR** (400 MHz, CDCl_3) δ 7.45 (d, $J = 8.5$ Hz, 2H), 7.39 – 7.33 (m, 2H), 7.37 – 7.32 (m, 1H, minor), 4.52 (d, $J = 7.5$ Hz, 1H, minor), 4.35 (d, $J = 8.6$ Hz, 1H), 4.27 (d, $J = 9.1$ Hz, 1H), 4.17 (d, $J = 8.8$ Hz, 1H, minor), 4.09 (d, $J = 9.2$ Hz, 1H), 4.06 – 3.98 (m, 1H), 3.97 (s, 1H), 3.94 – 3.89 (m, 2H, minor), 3.86 (s, 1H, minor), 3.79 (d, $J = 9.6$ Hz, 1H), 3.48 (d, $J = 7.5$ Hz, 1H, minor), 3.16 (d, $J = 8.6$ Hz, 1H), 2.51 (brs, 1H), 1.56 (s, 9H, minor), 1.53 (s, 9H), 1.45 (s, 9H), 1.43 (s, 9H, minor). **13C NMR** (100 MHz, CDCl_3) δ (major + minor) 170.7, 169.7, 155.6, 155.4, 137.8, 136.8, 134.5, 129.2 (2C), 129.0, 128.4, 128.0 (2C), 117.3, 116.1, 83.6, 83.2, 80.3, 66.8, 66.6, 63.5, 61.1, 57.5, 54.6, 46.6, 46.3, 45.0, 44.6, 28.4 (3C), 28.1 (3C), 28.0. **HRMS** (ESI-TOF) calcd for $[\text{C}_{23}\text{H}_{30}\text{ClN}_3\text{O}_4+\text{H}]^+$: 448.1998, found: 448.2002; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) $t_R = 8.63$ min, 15.91 min.



2-(*tert*-Butyl) 5-methyl (5*S*,7*R*,8*R*)-7-(2-chlorophenyl)-8-cyano-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate


White solid, yield: 96%; m.p.: 156–158 °C; $[\alpha]_D^{25} = +215.4(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **1H NMR** (400 MHz, CDCl_3) δ 7.80 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.38 (dd, $J = 7.7, 1.6$ Hz, 1H), 7.35 – 7.21 (m, 2H), 4.98 (d, $J = 5.3$ Hz, 1H), 4.88 (d, $J = 7.0$ Hz, 1H, minor), 4.31 – 4.19 (m, 3H), 4.06 (s, 2H, minor), 4.02 (s, 1H, minor), 3.96 (d, $J = 9.0$ Hz, 1H, minor), 3.86 (s, 3H), 3.79 (d, $J = 9.8$ Hz, 1H), 3.74 (d, $J = 7.1$ Hz, 1H, minor), 3.46 (d, $J = 9.8$ Hz, 1H), 3.35 (d, $J = 5.3$ Hz, 1H), 2.61 (brs, 1H), 1.42 (s, 9H). **13C NMR** (100 MHz, CDCl_3) δ 171.8, 155.8, 137.6, 132.9, 129.8, 129.6, 127.8, 127.5, 117.7, 80.3, 65.4, 60.0, 56.0, 56.0, 52.6, 45.8, 44.6, 28.3 (3C). **HRMS** (ESI-TOF) calcd for $[\text{C}_{20}\text{H}_{24}\text{ClN}_3\text{O}_4+\text{H}]^+$: 406.1528, found: 406.1533; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) $t_R = 8.36$ min, 17.57 min.




2-(*tert*-Butyl) 5-methyl (5*S*,7*R*,8*R*)-7-(3-chlorophenyl)-8-cyano-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate

White solid, yield: 98%; m.p.: 165–167 °C; $[\alpha]_D^{25} = +181.4(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **1H NMR** (400 MHz, CDCl_3) δ 7.53 (s, 1H), 7.40 – 7.35 (m, 1H), 7.34 – 7.31 (m, 2H), 4.50 (d, $J = 7.2$ Hz, 1H, minor), 4.35 (d, $J = 9.2$ Hz, 1H), 4.29 (d, $J = 9.2$ Hz, 1H), 4.13 (s, 1H), 4.06 (d, $J = 9.2$ Hz, 1H), 3.94 (d, $J = 9.7$ Hz, 1H), 3.90 – 3.87 (m, 1H), 3.84 (s, 3H), 3.49 (d, $J = 6.9$ Hz, 1H, minor), 3.25 (d, $J = 9.2$ Hz, 1H), 2.57 (brs, 1H), 1.46 (s, 9H). **13C NMR** (100 MHz, CDCl_3) δ 172.2, 155.8, 141.1, 135.0, 130.3,


129.0, 126.8, 125.0, 116.9, 80.4, 66.2, 63.6, 58.1, 54.3, 52.7, 45.9, 45.2, 28.3 (3C). **HRMS** (ESI-TOF) calcd for $[C_{20}H_{24}ClN_3O_4+H]^+$: 406.1528, found: 406.1532; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 8.18 min, 24.12 min.



2-(*tert*-Butyl) 5-methyl (5*S*,7*R*,8*R*)-7-(4-bromophenyl)-8-cyano-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 98%; m.p.: 169–171°C; $[\alpha]_D^{25} = +152.7(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **¹H NMR** (400 MHz, CDCl₃) δ 7.51 (d, $J = 8.2$ Hz, 2H), 7.40 (d, $J = 8.2$ Hz, 2H), 7.35 (d, $J = 8.2$ Hz, 2H, minor), 4.49 (d, $J = 6.9$ Hz, 1H, minor), 4.33 (d, $J = 9.5$ Hz, 1H), 4.29 (d, $J = 9.1$ Hz, 1H), 4.13 (s, 1H), 4.05 (d, $J = 9.1$ Hz, 1H), 4.04 – 3.96 (m, 3H, minor), 3.93 (d, $J = 9.8$ Hz, 1H), 3.90 – 3.85 (m, 1H), 3.83 (s, 3H), 3.48 (d, $J = 6.9$ Hz, 1H, minor), 3.22 (d, $J = 9.2$ Hz, 1H), 2.55 (brs, 1H), 1.45 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ 172.4, 155.8, 138.0, 132.1 (2C), 128.4 (2C), 122.8, 116.9, 80.4, 66.2, 63.6, 58.4, 54.2, 52.7, 46.0, 45.3, 28.3 (3C). **HRMS** (ESI-TOF) calcd for $[C_{20}H_{24}^{79}\text{Br}N_3O_4+H]^+$: 450.1023, found: 450.1027, $[C_{20}H_{24}^{81}\text{Br}N_3O_4+H]^+$: 452.1002, found: 452.1006; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 10.99 min, 17.97 min.




2-(*tert*-Butyl) 5-methyl (5*S*,7*R*,8*R*)-8-cyano-7-(4-cyanophenyl)-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 97%; m.p.: 164–166°C; $[\alpha]_D^{25} = +185.3(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **¹H NMR** (400 MHz, CDCl₃) δ 7.68 (s, 4H), 4.62 (d, $J = 7.2$ Hz, 1H, minor), 4.46 (d, $J = 9.3$ Hz, 1H), 4.29 (d, $J = 9.1$ Hz, 1H), 4.18 (s, 1H), 4.05 (d, $J = 9.2$ Hz, 1H), 3.96 – 3.85 (m, 2H), 3.84 (s, 3H), 3.55 (d, $J = 7.2$ Hz, 1H, minor) 3.28 (d, $J = 9.3$ Hz, 1H), 2.66 (brs, 1H), 1.45 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ 172.3, 155.7, 144.7, 132.7 (2C), 127.5 (2C), 118.4, 116.6, 112.6, 80.5, 66.0, 63.4, 58.2, 53.9, 52.7, 45.7, 45.3, 28.3 (3C). **HRMS** (ESI-TOF) calcd for $[C_{21}H_{24}N_4O_4+H]^+$: 397.1870, found: 397.1874; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 14.13 min, 25.44 min.




2-(*tert*-Butyl) 5-methyl (5*S*,7*R*,8*R*)-8-cyano-7-(4-fluorophenyl)-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 96%; m.p.: 151–153 °C; $[\alpha]_D^{25} = +162.5(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **¹H NMR** (400 MHz, CDCl₃) δ 7.54 – 7.44 (m, 2H), 7.14 – 6.95 (m, 2H), 4.52 (d, $J = 7.0$ Hz, 1H, minor), 4.35 (d, $J = 9.4$ Hz, 1H), 4.30 (d, $J = 9.2$ Hz, 1H), 4.12 (s, 1H), 4.06 (d, $J = 9.2$ Hz, 1H), 3.95 (d, $J = 9.7$ Hz, 1H), 3.87 (d, $J = 9.1$ Hz, 1H), 3.83 (s, 3H), 3.47 (d, $J = 7.0$ Hz, 1H, minor), 3.22 (d, $J = 9.3$ Hz, 1H), 2.54 (brs,


1H), 1.46 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ 172.5, 162.9 (d, *J* = 247.4 Hz), 155.8, 134.6, 128.4 (d, *J* = 8.2 Hz, 2C), 117.0, 115.9 (d, *J* = 21.6 Hz, 2C), 80.4, 66.2, 63.5, 58.4, 54.3, 52.6, 46.1, 45.2, 28.3 (3C). **HRMS** (ESI-TOF) calcd for [C₂₀H₂₄FN₃O₄+H]⁺: 390.1824, found: 390.1830; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 10.30 min, 16.31 min.



2-(tert-Butyl) 5-methyl (5*S*,7*R*,8*R*)-8-cyano-7-(*o*-tolyl)-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 97%; m.p.: 139–141 °C; [α]_D²⁵ = +153.6 (*c* 1.00, CH₂Cl₂); **¹H NMR** (400 MHz, CDCl₃) δ 7.66 (d, *J* = 7.5 Hz, 1H, minor), 7.60 (dd, *J* = 7.2, 1.9 Hz, 1H), 7.33 – 7.11 (m, 3H), 4.69 (d, *J* = 8.0 Hz, 1H), 4.29 (d, *J* = 9.2 Hz, 1H), 4.15 (d, *J* = 9.5 Hz, 1H), 4.13 (s, 1H), 4.06 (s, 2H, minor), 3.95 (d, *J* = 9.8 Hz, 1H), 3.88 (s, 3H, minor), 3.85 (s, 3H), 3.77 (d, *J* = 9.7 Hz, 1H), 3.52 (d, *J* = 7.1 Hz, 1H, minor), 3.23 (d, *J* = 8.0 Hz, 1H), 2.44 (s, 4H), 2.35 (s, 3H, minor), 1.45 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ 172.1, 155.8, 137.1, 136.1, 130.9, 128.4, 126.9, 125.5, 117.6, 80.3, 66.2, 60.0, 57.4, 55.1, 52.7, 45.4, 45.2, 28.3 (3C), 19.5. **HRMS** (ESI-TOF) calcd for [C₂₁H₂₇N₃O₄+H]⁺: 386.2074, found: 386.2078; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 8.90 min, 13.61 min.




2-(tert-Butyl) 5-methyl (5*S*,7*R*,8*R*)-8-cyano-7-(*m*-tolyl)-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 97%; m.p.: 142–144 °C; [α]_D²⁵ = +174.5 (*c* 1.00, CH₂Cl₂); **¹H NMR** (400 MHz, CDCl₃) δ 7.33 – 7.23 (m, 3H), 7.20 – 7.13 (m, 1H), 4.47 (d, *J* = 6.8 Hz, 1H, minor), 4.31 (d, *J* = 9.0 Hz, 2H), 4.15 (d, *J* = 9.0 Hz, 1H, minor), 4.11 (s, 1H), 4.08 (d, *J* = 9.2 Hz, 1H), 3.96 (d, *J* = 9.7 Hz, 1H), 3.91 – 3.83 (m, 1H), 3.84 (s, 3H), 3.47 (d, *J* = 6.8 Hz, 1H, minor), 3.23 (d, *J* = 9.1 Hz, 1H), 2.37 (s, 3H), 1.46 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ 172.3, 155.8, 138.7, 138.6, 129.5, 128.9, 127.3, 123.6, 117.2, 80.3, 66.4, 64.4, 58.2, 54.6, 52.6, 46.1, 45.3, 28.3 (3C), 21.4. **HRMS** (ESI-TOF) calcd for [C₂₁H₂₇N₃O₄+H]⁺: 386.2074, found: 386.2079; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 9.27 min, 22.53 min.




2-(tert-Butyl) 5-methyl (5*S*,7*R*,8*R*)-8-cyano-7-(*p*-tolyl)-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 97%; m.p.: 171–173 °C; [α]_D²⁵ = +192.7 (*c* 1.00, CH₂Cl₂); **¹H NMR** (400 MHz, CDCl₃) δ 7.36 (d, *J* = 7.9 Hz, 2H), 7.19 (d, *J* = 7.8 Hz, 2H), 4.48 (d, *J* = 6.9 Hz, 1H, minor), 4.31 (dd, *J* = 9.4, 2.6 Hz, 2H), 4.15 (d, *J* = 9.0 Hz, 1H, minor), 4.10 (s, 1H), 4.07 (d, *J* = 9.2 Hz, 1H), 4.02 (d, *J* = 6.2 Hz,


2H, minor), 3.95 (d, J = 9.7 Hz, 1H), 3.90 – 3.85 (m, 1H), 3.83 (s, 3H), 3.46 (d, J = 6.8 Hz, 1H, minor), 3.21 (d, J = 9.2 Hz, 1H), 2.51 (brs, 1H), 2.35 (s, 3H), 1.45 (s, 9H). **^{13}C NMR** (100 MHz, CDCl_3) δ 172.4, 155.8, 138.7, 135.6, 129.7 (2C), 126.5 (2C), 117.2, 80.3, 66.5, 64.2, 57.9, 54.5, 52.6, 46.2, 45.3, 28.3 (3C), 21.2. **HRMS** (ESI-TOF) calcd for $[\text{C}_{21}\text{H}_{27}\text{N}_3\text{O}_4+\text{H}]^+$: 386.2074, found: 386.2079; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_{R} = 9.56 min, 11.74 min.



2-(*tert*-Butyl) 5-methyl (*5S,7R,8R*)-8-cyano-7-(2-methoxyphenyl)-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 97%; m.p.: 145–147 °C; $[\alpha]_D^{25} = +234.7(c 1.00, \text{CH}_2\text{Cl}_2)$; **^1H NMR** (400 MHz, CDCl_3) δ 7.49 (dd, J = 7.6, 1.7 Hz, 1H), 7.36 – 7.26 (m, 1H), 7.02 – 6.93 (m, 1H), 6.90 (d, J = 8.2 Hz, 1H), 4.73 (d, J = 7.5 Hz, 1H, minor), 4.64 (d, J = 6.6 Hz, 1H), 4.29 (d, J = 9.4 Hz, 1H), 4.18 (d, J = 9.4 Hz, 1H), 4.08 (s, 1H), 4.02 (d, J = 8.6 Hz, 1H, minor), 3.89 – 3.78 (m, 7H), 3.62 (d, J = 9.7 Hz, 1H), 3.36 (d, J = 6.7 Hz, 1H), 2.86 (brs, 1H), 1.44 (s, 9H). **^{13}C NMR** (100 MHz, CDCl_3) δ 171.4, 156.8, 155.9, 129.7, 128.0, 126.6, 121.0, 118.5, 110.6, 80.2, 66.4, 61.1, 56.7, 55.3 (2C), 52.6, 45.6, 45.3, 28.3 (3C). **HRMS** (ESI-TOF) calcd for $[\text{C}_{21}\text{H}_{27}\text{N}_3\text{O}_5+\text{H}]^+$: 402.2023, found: 402.2027; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_{R} = 12.22 min, 27.45 min.




2-(*tert*-Butyl) 5-methyl (*5S,7R,8R*)-8-cyano-7-phenyl-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 96%; m.p.: 154–156 °C; $[\alpha]_D^{25} = +183.8(c 1.00, \text{CH}_2\text{Cl}_2)$; **^1H NMR** (400 MHz, CDCl_3) δ 7.53 – 7.46 (m, 2H), 7.45 – 7.32 (m, 3H), 4.52 (d, J = 6.4 Hz, 1H, minor), 4.48 (s, 1H, minor), 4.36 (d, J = 9.2 Hz, 1H), 4.31 (d, J = 9.2 Hz, 1H), 4.12 (s, 1H), 4.08 (d, J = 9.2 Hz, 1H), 3.96 (d, J = 9.7 Hz, 1H), 3.91 – 3.83 (m, 1H), 3.84 (s, 3H), 3.49 (d, J = 6.9 Hz, 1H, minor), 3.25 (d, J = 9.2 Hz, 1H), 2.56 (brs, 1H), 1.46 (s, 9H). **^{13}C NMR** (100 MHz, CDCl_3) δ 172.4, 155.8, 138.7, 129.0 (2C), 128.8, 126.6 (2C), 117.2, 80.3, 66.4, 64.3, 58.0, 54.5, 52.6, 46.1, 45.3, 28.3 (3C). **HRMS** (ESI-TOF) calcd for $[\text{C}_{20}\text{H}_{25}\text{N}_3\text{O}_4+\text{H}]^+$: 372.1918.2074, found: 372.1922; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_{R} = 9.35 min, 16.26 min.




2-(*tert*-Butyl) 5-methyl (*5S,7R,8R*)-8-cyano-7-(naphthalen-2-yl)-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 98%; m.p.: 158–160 °C; $[\alpha]_D^{25} = +221.4(c 1.00, \text{CH}_2\text{Cl}_2)$; **^1H NMR**


(400 MHz, CDCl₃) δ 7.96 – 7.90 (m, 1H), 7.91 – 7.80 (m, 3H), 7.61 (dd, *J* = 8.6, 1.8 Hz, 1H), 7.55 – 7.46 (m, 2H), 4.67 (d, *J* = 7.1 Hz, 1H, minor), 4.53 (d, *J* = 9.1 Hz, 1H), 4.35 (d, *J* = 9.1 Hz, 1H), 4.17 (s, 1H), 4.11 (d, *J* = 9.2 Hz, 1H), 4.10 – 4.02 (m, 2H, minor), 3.98 (d, *J* = 9.7 Hz, 1H), 3.94 – 3.87 (m, 1H), 3.87 (s, 3H), 3.56 (d, *J* = 6.9 Hz, 1H, minor), 3.35 (d, *J* = 9.1 Hz, 1H), 2.65 (brs, 1H), 1.46 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 172.4, 155.8, 136.0, 133.5, 133.2, 129.1, 128.1, 127.8, 126.6, 126.5, 126.2, 123.9, 117.2, 80.4, 66.4, 64.5, 58.2, 54.5, 52.7, 46.0, 45.3, 28.3 (3C). HRMS (ESI-TOF) calcd for [C₂₄H₂₇N₃O₄+H]⁺: 422.2074, found: 422.2078; HPLC (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 14.71 min, 24.49 min.




2-(*tert*-Butyl) 5-methyl (5*S*,7*R*,8*R*)-8-cyano-7-(thiophen-2-yl)-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 97%; m.p.: 119–121 °C; [α]_D²⁵ = +173.5 (*c* 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.28 (dd, *J* = 5.2, 1.3 Hz, 1H), 7.15 (d, *J* = 3.5 Hz, 1H), 6.99 (dd, *J* = 5.1, 3.5 Hz, 1H), 4.78 (d, *J* = 7.2 Hz, 1H, minor), 4.68 (d, *J* = 8.6 Hz, 1H), 4.28 (d, *J* = 9.2 Hz, 1H), 4.17 (d, *J* = 9.0 Hz, 1H, minor), 4.09 (s, 1H), 4.06 (d, *J* = 9.3 Hz, 1H), 3.94 (d, *J* = 9.8 Hz, 1H), 3.91 – 3.84 (m, 1H), 3.83 (s, 3H), 3.50 (d, *J* = 7.1 Hz, 1H, minor), 3.34 (d, *J* = 8.6 Hz, 1H), 2.71 (brs, 1H), 1.45 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 171.8, 155.8, 143.1, 127.3, 125.7, 125.3, 117.0, 80.4, 66.2, 60.0, 57.6, 54.6, 52.6, 46.7, 45.2, 28.3 (3C). HRMS (ESI-TOF) calcd for [C₁₈H₂₃N₃O₄S+H]⁺: 378.1482, found: 378.1486; HPLC (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 10.98 min, 26.59 min.




2-(*tert*-Butyl) 5-methyl (5*S*,7*S*,8*R*)-8-cyano-7-cyclohexyl-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 92%; m.p.: 132–134 °C; [α]_D²⁵ = +138.5 (*c* 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 4.24 (d, *J* = 9.2 Hz, 1H), 4.01 (d, *J* = 9.3 Hz, 1H), 3.92 – 3.85 (m, 2H), 3.86 – 3.79 (m, 1H), 3.79 (s, 3H), 3.13 – 3.04 (m, 1H), 2.97 (d, *J* = 8.6 Hz, 1H), 2.17 (s, 1H), 1.86 – 1.65 (m, 6H), 1.45 (s, 9H), 1.32 – 1.01 (m, 5H). ¹³C NMR (100 MHz, CDCl₃) δ 171.8, 155.8, 118.5, 80.2, 66.4, 66.3, 57.4, 55.4, 52.5, 45.2, 42.5, 41.2, 29.9, 29.7, 28.3 (3C), 26.1, 25.8, 25.7. HRMS (ESI-TOF) calcd for [C₂₀H₃₁N₃O₄+H]⁺: 378.2387, found: 378.2391; HPLC (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 7.55 min, 9.55 min.




2-(*tert*-Butyl) 5-methyl (5*S*,7*R*,8*R*)-7-(*tert*-butyl)-8-cyano-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 91%; m.p.: 142–144 °C; $[\alpha]_D^{25} = +178.6$ (*c* 1.00, CH₂Cl₂); **¹H NMR** (400 MHz, CDCl₃) δ 4.24 (d, *J* = 9.4 Hz, 1H), 4.05 (d, *J* = 9.3 Hz, 1H), 3.88 (s, 1H), 3.86 – 3.80 (m, 2H), 3.78 (s, 3H), 3.16 (d, *J* = 8.2 Hz, 1H), 3.03 (d, *J* = 8.3 Hz, 1H), 2.23 (s, 1H), 1.44 (s, 9H), 0.97 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ 171.1, 155.8, 119.0, 80.1, 70.4, 65.9, 56.5, 56.1, 52.4, 45.0, 39.0, 33.6, 28.3 (3C), 26.1 (3C). **HRMS** (ESI-TOF) calcd for [C₁₈H₂₉N₃O₄+H]⁺: 352.2231, found: 352.2236; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 8.78 min, 9.36 min.



2-(*tert*-Butyl) 5,8-dimethyl (5*S*,7*R*,8*R*)-7-(4-chlorophenyl)-2,6-diazaspiro[3.4]octane-2,5,8-tricarboxylate White solid, yield: 94%; m.p.: 153–155 °C; $[\alpha]_D^{25} = +156.4$ (*c* 1.00, CH₂Cl₂); **¹H NMR** (400 MHz, CDCl₃) δ 7.41 (d, *J* = 8.3 Hz, 2H), 7.29 (d, *J* = 8.5 Hz, 2H), 4.48 (d, *J* = 7.9 Hz, 1H), 4.13 (s, 1H), 4.08 (d, *J* = 8.3 Hz, 1H, minor), 4.06 – 3.94 (m, 2H), 3.94 – 3.84 (m, 2H), 3.83 (s, 3H), 3.73 (s, 3H), 3.41 (d, *J* = 6.8 Hz, 1H, minor), 3.34 (s, 2H, minor), 3.12 (d, *J* = 8.0 Hz, 1H), 2.46 (brs, 1H), 1.43 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ (minor + major) 172.6, 171.8, 171.5, 170.6, 156.0, 140.1, 133.6, 128.8, 128.6, 128.3, 127.9, 79.9, 68.6, 67.3, 63.2, 62.6, 59.2, 57.2, 55.4, 52.5, 52.4, 52.3, 51.5, 45.5, 28.3 (3C). **HRMS** (ESI-TOF) calcd for [C₂₁H₂₇ClN₂O₆+H]⁺: 439.1630, found: 439.1634; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 28.26 min, 32.83 min.




2-(*tert*-Butyl) 8-ethyl 5-methyl (5*S*,7*R*,8*R*)-7-(4-chlorophenyl)-2,6-diazaspiro[3.4]octane-2,5,8-tricarboxylate White solid, yield: 99%; m.p.: 156–158 °C; $[\alpha]_D^{25} = +164.4$ (*c* 1.00, CH₂Cl₂); **¹H NMR** (400 MHz, CDCl₃) δ 7.42 (d, *J* = 8.1 Hz, 2H), 7.30 (d, *J* = 6.7 Hz, 2H), 4.48 (d, *J* = 7.9 Hz, 1H), 4.29 – 4.19 (m, 1H), 4.17 – 4.05 (m, 2H), 4.07 – 3.94 (m, 2H), 3.93 – 3.85 (m, 2H), 3.83 (s, 3H), 3.39 (d, *J* = 6.7 Hz, 1H, minor), 3.10 (d, *J* = 8.2 Hz, 1H), 2.44 (brs, 1H), 1.42 (s, 9H), 1.25 (t, *J* = 7.1 Hz, 3H). **¹³C NMR** (100 MHz, CDCl₃) δ (minor + major) 172.8, 171.7, 170.9, 170.2, 156.1, 155.9, 140.2, 133.6, 133.5, 128.8 (2C), 128.5, 128.4 (2C), 128.0, 79.9, 79.8, 68.8, 67.4, 63.2, 62.5, 61.3, 60.7, 59.8, 59.0, 52.5, 52.4, 46.9, 45.5, 28.4 (3C), 28.4 (3C), 14.2, 13.8. **HRMS** (ESI-TOF) calcd for [C₂₂H₂₉ClN₂O₆+H]⁺: 453.1787, found: 453.1791; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 14.30 min, 16.99 min.




Methyl (5S,7R,8R)-7-(4-chlorophenyl)-8-cyano-2-tosyl-2,6-diazaspiro[3.4]octane-5-carboxylate


White solid, yield: 75%; m.p.: 173–175 °C; $[\alpha]_D^{25} = +170.4$ (*c* 1.00, CH_2Cl_2); **1H NMR** (400 MHz, CDCl_3) δ 7.74 (d, *J* = 8.3 Hz, 2H), 7.38 (dd, *J* = 8.5, 2.5 Hz, 4H), 7.36 – 7.29 (m, 2H), 4.27 (d, *J* = 9.0 Hz, 1H), 4.05 (s, 1H), 4.02 – 3.97 (m, 2H), 3.87 (d, *J* = 9.0 Hz, 1H), 3.77 (s, 3H), 3.61 (d, *J* = 9.0 Hz, 1H), 3.07 (d, *J* = 9.0 Hz, 1H), 2.45 (s, 3H). **13C NMR** (100 MHz, CDCl_3) δ 172.0, 144.9, 137.3, 134.6, 131.0, 130.0 (2C), 129.1 (2C), 128.3 (2C), 127.9 (2C), 116.4, 65.6, 63.4, 58.2, 55.2, 52.7, 45.5, 44.7, 21.6. **HRMS** (ESI-TOF) calcd for $[\text{C}_{22}\text{H}_{22}\text{ClN}_3\text{O}_4\text{S}+\text{H}]^+$: 460.1092, found: 460.1096; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 17.85 min, 21.31 min.



Methyl (5S,7R,8R)-7-(4-chlorophenyl)-8-cyano-2-oxa-6-azaspiro[3.4]octane-5-carboxylate White solid, yield: 86%; m.p.: 144–146 °C; $[\alpha]_D^{25} = +188.0$ (*c* 1.00, CH_2Cl_2); **1H NMR** (400 MHz, CDCl_3) δ 7.49 – 7.40 (m, 2H), 7.38 – 7.30 (m, 2H), 5.00 (d, *J* = 6.8 Hz, 1H), 4.79 (d, *J* = 6.9 Hz, 1H), 4.67 (d, *J* = 7.5 Hz, 1H), 4.59 (d, *J* = 7.5 Hz, 1H), 4.29 (d, *J* = 9.4 Hz, 1H), 4.24 (s, 1H), 3.85 (s, 3H), 3.21 (d, *J* = 9.4 Hz, 1H), 2.55 (brs, 1H). **13C NMR** (100 MHz, CDCl_3) δ 172.4, 137.3, 134.6, 129.2 (2C), 128.0 (2C), 117.1, 79.0, 75.5, 65.6, 63.5, 52.7, 50.8, 45.5. **HRMS** (ESI-TOF) calcd for $[\text{C}_{15}\text{H}_{15}\text{ClN}_2\text{O}_3+\text{H}]^+$: 307.0844, found: 307.0848; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 31.21 min, 37.76 min.




Dimethyl (5S,7R,8R)-7-(4-chlorophenyl)-2-oxa-6-azaspiro[3.4]octane-5,8-dicarboxylate White solid, yield: 91%; m.p.: 154–156 °C; $[\alpha]_D^{25} = +156.3$ (*c* 1.00, CH_2Cl_2); **1H NMR** (400 MHz, CDCl_3) δ 7.39 (d, *J* = 8.2 Hz, 2H), 7.30 (d, *J* = 8.4 Hz, 2H), 4.75 (d, *J* = 6.9 Hz, 1H), 4.71 (d, *J* = 6.8 Hz, 1H), 4.65 (d, *J* = 7.0 Hz, 1H), 4.54 (d, *J* = 7.0 Hz, 1H), 4.44 (d, *J* = 8.2 Hz, 1H), 4.20 (s, 1H), 3.86 (s, 3H), 3.77 (s, 3H), 3.14 (d, *J* = 8.2 Hz, 1H), 2.26 (brs, 1H). **13C NMR** (100 MHz, CDCl_3) δ 172.7, 171.6, 139.9, 133.6, 128.8 (2C), 128.2 (2C), 78.1, 77.4, 66.7, 62.7, 58.8, 52.5, 52.4, 51.4. **HRMS** (ESI-TOF) calcd for $[\text{C}_{16}\text{H}_{18}\text{ClNO}_5+\text{H}]^+$: 340.0946, found: 340.0951; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 18.84 min, 23.48 min.




Methyl (5S,7R,8R)-7-(4-chlorophenyl)-8-cyano-2-thia-6-azaspiro[3.4]octane-5-carboxylate White solid, yield: 93%; m.p.: 140–142 °C; $[\alpha]_D^{25} = +163.4$ (*c* 1.00, CH_2Cl_2); **1H NMR** (400 MHz, CDCl_3) δ


7.48 (d, $J = 8.5$ Hz, 2H), 7.35 (d, $J = 8.5$ Hz, 2H), 4.38 (d, $J = 9.3$ Hz, 1H), 4.27 (s, 1H), 4.13 (s, 1H, minor), 3.85 (s, 3H), 3.67 (d, $J = 9.8$ Hz, 1H), 3.49 – 3.39 (m, 2H, minor), 3.31 – 3.21 (m, 2H), 3.17 (dd, $J = 9.8, 6.3$ Hz, 2H), 2.54 (brs, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 172.7, 137.8, 134.5, 129.1 (2C), 128.2 (2C), 117.4, 67.9, 62.9, 55.0, 52.6, 47.9, 34.1, 30.5. HRMS (ESI-TOF) calcd for $[\text{C}_{15}\text{H}_{15}\text{ClN}_2\text{O}_2\text{S}+\text{H}]^+$: 323.0616, found: 323.0620; HPLC (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 23.89 min, 27.14 min.



8-Ethyl 5-methyl (5*S*,7*R*,8*R*)-7-(4-chlorophenyl)-2-thia-6-azaspiro[3.4]octane-5,8-dicarboxylate White solid, yield: 93%; m.p.: 148–150 °C; $[\alpha]_D^{25} = +136.4$ (c 1.00, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.45 (d, $J = 8.5$ Hz, 2H), 7.29 (d, $J = 8.5$ Hz, 2H), 4.51 (d, $J = 9.1$ Hz, 1H), 4.32 – 4.16 (m, 2H), 4.16 (s, 1H), 3.84 (s, 3H), 3.48 (d, $J = 9.8$ Hz, 1H), 3.36 (d, $J = 9.9$ Hz, 1H), 3.26 (d, $J = 9.8$ Hz, 1H), 3.21 (d, $J = 9.9$ Hz, 1H), 3.05 (d, $J = 9.2$ Hz, 1H), 2.36 (brs, 1H), 1.29 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 173.1, 170.9, 140.2, 133.4, 128.7 (2C), 128.5 (2C), 69.3, 62.0, 61.4, 59.9, 56.0, 52.3, 33.5, 31.4, 14.2. HRMS (ESI-TOF) calcd for $[\text{C}_{17}\text{H}_{20}\text{ClNO}_4\text{S}+\text{H}]^+$: 370.0880, found: 370.0884; HPLC (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 14.03 min, 15.88 min.




8-(*tert*-Butyl) 1-methyl (1*S*,3*R*,4*R*)-3-(4-chlorophenyl)-4-cyano-2,8-diazaspiro[4.5]decane-1,8-dicarboxylate White solid, yield: 86%; m.p.: 168–170 °C; $[\alpha]_D^{25} = +157.5$ (c 1.00, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, $J = 8.5$ Hz, 2H), 7.36 (d, $J = 8.5$ Hz, 2H), 4.49 (d, $J = 10.1$ Hz, 1H), 4.02 (s, 2H), 3.79 (s, 3H), 3.77 – 3.66 (m, 1H), 3.34 – 3.09 (m, 2H), 3.00 (d, $J = 10.1$ Hz, 1H), 2.52 (s, 1H), 2.01 – 1.65 (m, 4H), 1.47 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 173.6, 154.6, 138.4, 134.3, 129.0 (2C), 128.4 (2C), 117.7, 80.1, 65.0, 63.3, 52.2, 48.4, 47.7, 40.6, 39.9, 31.5, 31.3, 28.4 (3C). HRMS (ESI-TOF) calcd for $[\text{C}_{22}\text{H}_{28}\text{ClN}_3\text{O}_4+\text{H}]^+$: 434.1841, found: 434.1846; HPLC (Chiralpak AD-H, *n*-hexane/*i*-propanol = 80/20, 1.0 mL/min, 220 nm) t_R = 8.05 min, 11.87 min.




At a nitrogen atmosphere, $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (3.1 mg, 0.01 mmol), Cs_2CO_3 (65.2 mg, 0.2 mmol) and **L7** (5.8 mg, 0.011 mmol) were dissolved in 2.0 mL dry CH_2Cl_2 , subsequently add 4 Å Ms (100 mg), and stirred at room temperature for about 1–2 h. Then, iminoester **1** (0.24 mmol) were added, the mixture was


cooled to -20 °C and alkene **2** (0.2 mmol) was added. Once starting material was consumed (monitored by TLC), the mixture was concentrated and the residue was purified by column chromatography (petroleum ether/ethyl acetate 6:1 to 2:1) on silica gel to afford the corresponding product **4**.



2-(*tert*-Butyl) 5-methyl (*5R,7S,8R*)-7-(4-chlorophenyl)-8-cyano-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 88%; m.p.: 176-178°C; $[\alpha]_D^{25} = +175.3(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **¹H NMR** (400 MHz, CDCl₃) δ 7.44 – 7.32 (m, 4H), 4.51 (d, *J* = 6.9 Hz, 1H), 4.16 (d, *J* = 8.9 Hz, 1H), 4.05 – 3.92 (m, 4H), 3.88 (s, 3H), 3.48 (d, *J* = 6.9 Hz, 1H), 2.69 (s, 1H), 1.44 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ 171.3, 155.9, 136.3, 134.6, 129.0 (2C), 128.4 (2C), 116.0, 80.4, 66.1, 61.2, 58.5, 54.6, 52.8, 46.4, 45.3, 28.3 (3C). **HRMS** (ESI-TOF) calcd for [C₂₀H₂₄ClN₃O₄+H]⁺: 406.1528, found: 450.1533; **HPLC** (Chiralpak AD-H, *n*-hexane/ethanol= 80/20, 0.8 mL/min, 220 nm) t_R = 15.81 min, 19.45 min.




2-(*tert*-Butyl) 5-methyl (*5R,7S,8R*)-7-(2-chlorophenyl)-8-cyano-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 91%; m.p.: 167-169 °C; $[\alpha]_D^{25} = +216.2(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **¹H NMR** (400 MHz, CDCl₃) δ 7.82 (dd, *J* = 7.6, 1.8 Hz, 1H), 7.44 – 7.34 (m, 2H), 7.33 – 7.27 (m, 1H), 4.88 (d, *J* = 7.0 Hz, 1H), 4.17 (d, *J* = 8.8 Hz, 1H), 4.07 (s, 2H), 4.02 (s, 1H), 3.96 (d, *J* = 8.9 Hz, 1H), 3.87 (s, 3H), 3.74 (d, *J* = 7.0 Hz, 1H), 2.61 (brs, 1H), 1.45 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ 171.1, 155.9, 135.3, 132.9, 129.8, 129.5, 128.0, 127.4, 115.9, 80.3, 65.7, 59.0, 58.1, 54.7, 52.7, 45.2, 44.8, 28.3 (3C). **HRMS** (ESI-TOF) calcd for [C₂₀H₂₄ClN₃O₄+H]⁺: 406.1528, found: 406.1533; **HPLC** (Chiralpak AD-H, *n*-hexane/ethanol= 80/20, 0.8 mL/min, 220 nm) t_R = 14.22 min, 15.82 min.




2-(*tert*-Butyl) 5-methyl (*5R,7S,8R*)-7-(4-bromophenyl)-8-cyano-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 80%; m.p.: 156-158 °C; $[\alpha]_D^{25} = +153.4(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **¹H NMR** (400 MHz, CDCl₃) δ 7.53 (d, *J* = 8.5 Hz, 2H), 7.35 (d, *J* = 8.5 Hz, 2H), 4.49 (d, *J* = 7.0 Hz, 1H), 4.15 (d, *J* = 8.9 Hz, 1H), 4.05 – 3.95 (m, 3H), 3.94 (d, *J* = 8.9 Hz, 1H), 3.88 (s, 3H), 3.48 (d, *J* = 7.0 Hz, 1H), 2.69 (s, 1H), 1.44 (s, 9H). **¹³C NMR** (100 MHz, CDCl₃) δ 171.3, 155.9, 136.9, 132.0 (2C), 128.7 (2C), 122.8, 116.0, 80.4, 66.1, 61.2, 58.5, 54.7, 52.8, 46.3, 45.2, 28.3 (3C). **HRMS** (ESI-TOF) calcd for [C₂₀H₂₄⁷⁹BrN₃O₄+H]⁺: 450.1023, found: 450.1027; for [C₂₀H₂₄⁸¹BrN₃O₄+H]⁺: 452.1002, found:

452.1006; **HPLC** (Chiralpak AD-H, *n*-hexane/ethanol= 80/20, 0.8 mL/min, 220 nm) t_R = 17.61 min, 21.48 min.




2-(*tert*-Butyl) 5-methyl (*5R,7S,8R*)-8-cyano-7-(o-tolyl)-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate

White solid, yield: 85%; m.p.: 151–153 °C; $[\alpha]_D^{25} = +152.8(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **1H NMR** (400 MHz, CDCl_3) δ 7.71 – 7.63 (m, 1H), 7.35 – 7.25 (m, 1H), 7.28 – 7.16 (m, 2H), 4.72 (d, $J = 7.2$ Hz, 1H), 4.29 (d, $J = 9.5$ Hz, 1H, minor), 4.19 (d, $J = 8.9$ Hz, 1H), 4.13 (s, 1H, minor), 4.06 (s, 2H), 3.99 (s, 1H), 3.94 (d, $J = 8.9$ Hz, 1H), 3.88 (s, 3H), 3.85 (s, 3H, minor), 3.52 (d, $J = 7.2$ Hz, 1H), 3.23 (d, $J = 8.1$ Hz, 1H, minor), 2.64 (brs, 1H), 2.44 (s, 3H, minor), 2.34 (s, 3H), 1.45 (s, 9H). **13C NMR** (100 MHz, CDCl_3) δ 171.2, 156.0, 135.8, 135.3, 130.7, 128.4, 126.7, 125.8, 116.1, 80.3, 66.0, 58.4, 57.9, 55.1, 52.7, 45.4, 45.2, 28.3 (3C), 19.6. **HRMS** (ESI-TOF) calcd for $[\text{C}_{21}\text{H}_{27}\text{N}_3\text{O}_4+\text{H}]^+$: 386.2074, found: 386.2078; **HPLC** (Chiralpak AD-H, *n*-hexane/ethanol= 80/20, 0.8 mL/min, 220 nm) t_R = 14.43 min, 19.30 min.



2-(*tert*-Butyl) 5-methyl (*5R,7S,8R*)-8-cyano-7-(thiophen-2-yl)-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate


White solid, yield: 78%; m.p.: 151–153 °C; $[\alpha]_D^{25} = +152.8(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **1H NMR** (400 MHz, CDCl_3) δ 7.31 (d, $J = 5.1$ Hz, 1H), 7.18 – 7.11 (m, 1H), 7.08 – 6.99 (m, 1H), 4.79 (d, $J = 7.0$ Hz, 1H), 4.17 (d, $J = 9.0$ Hz, 1H), 4.08 – 3.92 (m, 4H), 3.87 (s, 3H), 3.51 (d, $J = 6.9$ Hz, 1H), 2.61 (brs, 1H), 1.44 (s, 9H). **13C NMR** (100 MHz, CDCl_3) δ 170.8, 155.9, 142.0, 127.4, 125.8, 125.5, 115.9, 80.3, 66.1, 57.6, 57.4, 54.8, 52.8, 46.6, 45.1, 28.3 (3C). **HRMS** (ESI-TOF) calcd for $[\text{C}_{18}\text{H}_{23}\text{N}_3\text{O}_4\text{S}+\text{H}]^+$: 378.1482, found: 378.1487; **HPLC** (Chiralpak AD-H, *n*-hexane/ethanol= 80/20, 0.8 mL/min, 220 nm) t_R = 15.89 min, 22.61 min.



2-(*tert*-Butyl) 5,8-dimethyl (*5R,7S,8R*)-7-(4-chlorophenyl)-2,6-diazaspiro[3.4]octane-2,5,8-tricarboxylate


White solid, yield: 87%; m.p.: 163–165 °C; $[\alpha]_D^{25} = +155.9(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **1H NMR** (400 MHz, CDCl_3) δ 7.34 – 7.25 (m, 4H), 4.48 (d, $J = 6.8$ Hz, 1H), 4.15 – 4.05 (m, 2H), 4.02 (d, $J = 8.8$ Hz, 1H), 3.97 (s, 1H), 3.88 (s, 3H), 3.84 – 3.77 (m, 1H), 3.73 (s, 3H, minor), 3.41 (d, $J = 6.8$ Hz, 1H), 3.34 (s, 3H), 3.13 (d, $J = 7.8$ Hz, 1H, minor), 1.45 (s, 9H). **13C NMR** (100 MHz, CDCl_3) δ 171.8, 170.7, 156.1, 136.6, 133.6, 128.6 (2C), 127.9 (2C), 79.9, 68.6, 63.2, 61.5, 59.7, 54.5, 52.5, 51.6, 46.7, 28.4 (3C).

HRMS (ESI-TOF) calcd for [C₂₁H₂₇ClN₂O₆+H]⁺: 439.1630, found: 439.1634; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 90/10, 1.0 mL/min, 220 nm) t_R = 25.82 min, 28.76 min.




Methyl (5*R*,7*S*,8*R*)-7-(4-chlorophenyl)-8-cyano-2-oxa-6-azaspiro[3.4]octane-5-carboxylate White solid, yield: 85%; m.p.: 162–164 °C; [α]_D²⁵ = +187.6(*c* 1.00, CH₂Cl₂); **¹H NMR** (400 MHz, CDCl₃) δ 7.42 (d, *J* = 8.5 Hz, 2H), 7.38 (d, *J* = 8.4 Hz, 2H), 5.00 (d, *J* = 6.9 Hz, 1H, minor), 4.92 – 4.80 (m, 2H), 4.69 (d, *J* = 7.8 Hz, 1H), 4.60 (d, *J* = 6.6 Hz, 1H), 4.43 (d, *J* = 6.4 Hz, 1H), 4.25 (s, 1H, minor), 4.07 (s, 1H), 3.90 (s, 3H), 3.61 (d, *J* = 6.4 Hz, 1H), 3.21 (d, *J* = 9.5 Hz, 1H, minor), 2.67 (brs, 1H). **¹³C NMR** (100 MHz, CDCl₃) δ 171.5, 136.0, 134.7, 129.1 (2C), 128.4 (2C), 116.1, 80.2, 75.4, 65.4, 61.4, 52.9, 51.4, 46.2. **HRMS** (ESI-TOF) calcd for [C₁₅H₁₅ClN₂O₃+H]⁺: 307.0844, found: 307.0848; **HPLC** (Chiralpak AD-H, *n*-hexane/*i*-propanol = 90/10, 1.0 mL/min, 220 nm) t_R = 41.67 min, 43.80 min.

Gram scale procedure




Under a nitrogen atmosphere, Cu(CH₃CN)₄BF₄ (62.9 mg, 0.20 mmol) and **L6** (115.6 mg, 0.22 mmol) were dissolved in dry CH₂Cl₂ (40 mL), subsequently add 4Å Ms (800 mg), and stirred at room temperature for about 1 h. Then, glycine imine **1a** (1.02 g, 4.8 mmol) and Cs₂CO₃ (1.30 g, 4.0 mmol) were added, the mixture was cooled to -20 °C and alkene **2a** (0.78 g, 4.0 mmol) was added. Once starting material was consumed (monitored by TLC, about 2 h), the mixture was filtered through celite and the filtrate was concentrated, then the residue was purified by column chromatography (petroleum ether/ethyl acetate 4:1) on silica gel to afford the corresponding product **3aa** in 96% yield.




Under a nitrogen atmosphere, Cu(CH₃CN)₄BF₄ (62.9 mg, 0.20 mmol), Cs₂CO₃ (1.30 g, 4.0 mmol) and **L7** (115.9 mg, 0.22 mmol) were dissolved in dry CH₂Cl₂ (40 mL), subsequently add 4Å Ms (800 mg), and stirred at room temperature for about 1 h. Then, the mixture was cooled to -20 °C, glycine imine **1a** (1.02 g, 4.8 mmol) and alkene **2a** (0.78 g, 4.0 mmol) was added. Once starting material was consumed (monitored by TLC, about 3.5 h), the mixture was filtered through celite and the filtrate was concentrated, then the residue was purified by column chromatography (petroleum ether/ethyl acetate 4:1) on silica gel to afford the corresponding product **4aa** in 83% yield.


Synthetic transformations of the cycloadduct **3aa**




To a solution of **3aa** (40.6 mg, 0.1 mmol) in EtOAc (1 mL) was added hydrogen chloride (0.5 mL of a 4 M solution in EtOAc) and the mixture was stirred for 3 h, after which time the solvent was removed under reduced pressure. The crude product was purified by column chromatography (CH₂Cl₂/MeOH 10:1) on silica gel to afford the corresponding product **5** in 92% yield



Methyl (5*S*,7*R*,8*R*)-7-(4-chlorophenyl)-8-cyano-2,6-diazaspiro[3.4]octane-5-carboxylate White solid, yield: 92%; m.p.: 121–123 °C; $[\alpha]_D^{25} = +223.5(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **1H NMR** (400 MHz, CDCl_3) δ 7.48 (d, $J = 8.2$ Hz, 2H), 7.35 (d, $J = 8.2$ Hz, 2H), 4.30 (d, $J = 9.9$ Hz, 1H), 4.24 (s, 1H), 4.05 (dd, $J = 8.5, 1.7$ Hz, 1H), 3.82 (s, 3H), 3.75 – 3.64 (m, 2H), 3.61 (d, $J = 9.0$ Hz, 1H), 3.17 (d, $J = 9.9$ Hz, 1H), 2.12 (brs, 2H). **13C NMR** (100 MHz, CDCl_3) δ 173.3, 137.7, 134.4, 129.1 (2C), 128.2 (2C), 117.8, 66.5, 63.5, 56.1, 52.5, 51.8, 50.9, 45.9. **HRMS** (ESI-TOF) calcd for $[\text{C}_{15}\text{H}_{16}\text{ClN}_3\text{O}_2+\text{H}]^+$: 306.1004, found: 306.1007. **HPLC** (Chiralpak AD-H, *n*-hexane/ethanol = 70/30, 1.0 mL/min, 220 nm) $t_R = 9.12$ min, 21.32 min.



To a solution of **3aa** (40.6 mg, 0.1 mmol) in EtOH (1 mL) was added Raney Ni (8 mg) and the mixture was stirred at room temperature under H_2 atmosphere (bubble) for 4 h. The conversion was monitored by TLC. The resulting solution was filtered over Celite, and washed with EtOH and ethyl acetate. The solvent was removed under reduced pressure and the residue was purified by column chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 10:1) to afford the desired product **6** in 89% yield.



2-(*tert*-Butyl) 5-methyl (5*S*,7*R*,8*S*)-8-(aminomethyl)-7-(4-chlorophenyl)-2,6-diazaspiro[3.4]octane-2,5-dicarboxylate White solid, yield: 89%; m.p.: 155–157 °C; $[\alpha]_D^{25} = +176.5(c\ 1.00, \text{CH}_2\text{Cl}_2)$; **1H NMR** (400 MHz, CDCl_3) δ 7.80 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.38 (dd, $J = 7.7, 1.6$ Hz, 1H), 7.33 – 7.22 (m, 2H), 4.98 (d, $J = 5.3$ Hz, 1H), 4.88 (d, $J = 7.0$ Hz, 1H, minor), 4.28 – 4.17 (m, 3H), 4.06 (s, 2H, minor), 4.02 (s, 1H, minor), 3.96 (d, $J = 9.0$ Hz, 1H, minor), 3.86 (s, 3H), 3.79 (d, $J = 9.8$ Hz, 1H), 3.74 (d, $J = 7.1$ Hz, 1H, minor), 3.46 (d, $J = 9.8$ Hz, 1H), 3.35 (d, $J = 5.3$ Hz, 1H), 2.61 (s, 1H), 1.42 (s, 9H). **13C NMR** (100 MHz, CDCl_3) δ 173.4, 156.4, 141.2, 133.4, 128.9 (2C), 128.6 (2C), 79.9, 67.6, 64.8, 56.8, 55.9, 55.0, 52.3, 45.6, 40.5, 28.4 (3C). **HRMS** (ESI-TOF) calcd for $[\text{C}_{20}\text{H}_{28}\text{ClN}_3\text{O}_4+\text{H}]^+$: 410.1841, found: 410.1845. **HPLC** (Chiralpak AD-H, *n*-hexane/ethanol = 85/15, 1.0 mL/min, 220 nm) $t_R = 35.65$ min, 37.76 min.

Proposed transition states of the diastereodivergent asymmetric 1,3-dipolar cycloaddition

The diastereodivergent observed in this asymmetric 1,3-DC cycloaddition can be rationalized by the proposed transition state shown in Figure S1. With the ferrocene *P,N*-ligands **L6**, the *in situ*-formed azomethine ylide is coordinated to the metallic center and oriented in such way because of the steric repulsion between the phenyl group of the ylide and the phenyl ring on the phosphorus atom of the chiral ligand, and the highly steric congestion formation by the cyanogroup leads the dipolarophile (**2a**) approach azomethine ylide through *Re* (C=N) face attack and forms the *exo*-(*5S,7R,8R*)-**3aa** (**TS1**). With the *N,O*-ligands **L7**, the cyanogroup of **2a** could coordinate with the Cu(I) center, which can stabilize the negatively charged nitrogen atom in the proposed transition states (**TS2**).⁵ An *exo* approach of dipolarophile (**2a**) to the copper(I) complex occurred which is compatible with the experimental results.




Fig S1. Proposed transition states.

References

- (1) (a) A. López-Pérez, J. Adrio, J. C. Carretero, *J. Am. Chem. Soc.* 2008, **130**, 10084. (b) C.-J. Wang, G. Liang, Z.-Y. Xue, F. Gao, *J. Am. Chem. Soc.* 2008, **130**, 17250.
- (2) B. A. Chalyk, A. A. Isakov, M. V. Butko, K. V. Hrebeniuk, O. V. Savych, O. V. Kucher, K. S. Gavrilenko, T. V. Druzhenko, V. S. Yarmolchuk, S. Zozulya, and P. K. Mykhailiuk, *Eur. J. Org. Chem.* 2017, 4530.
- (3) J. Y. Cassayre, P. Renold, T. Pitterna, M. El Qacemi, WO2013026931A1, 2013.
- (4) E. Forcellini, S. Boutin, C.-A. Lefebvre, E. E. Shayhidin, M.-C. Boulanger, G. Rheaume, X. Barbeau, P. Lagüe, P. Mathieu, J.-F. Paquin, *Eur. J. Med. Chem.* 2018, **147**, 130.
- (5) (a) X.-X. Yan, Q. Peng, Y. Zhang, K. Zhang, W. Hong, X.-L. Hou, Y.-D. Wu, *Angew. Chem., Int. Ed.* 2006, **45**, 1979. (b) H. Y. Kim, H.-J. Shih, W. E. Knabe, K. Oh, *Angew. Chem., Int. Ed.* 2009, **48**, 7420. (c) T.-L. Liu, Z.-L. He, H.-Y. Tao, Y.-P. Cai and C.-J. Wang, *Chem. Commun.*, 2011, **47**, 2616-2618.

The absolute configuration determination of 3fa and 4fa




Fig S2. X-ray structure of (*5S,7R,8R*)-3fa

Ellipsoids are drawn at the 30% probability level.

Crystal data and structure refinement for CCDC 1914517

(CCDC 1914517 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html.)

Table S2. Crystal data and structure refinement for (*5S,7R,8R*)-3fa.

Identification code	(5S,7R,8R)-3fa		
Empirical formula	$C_{20} H_{24} Br N_3 O_4$		
Formula weight	450.33		
Temperature	296(2) K		
Wavelength	0.71073 Å		
Crystal system	Orthorhombic		
Space group	P 21 21 2		
Unit cell dimensions	$a = 10.2024(3)$ Å	$\alpha = 90^\circ$.	
	$b = 31.7463(10)$ Å	$\beta = 90^\circ$.	
	$c = 6.5544(2)$ Å	$\gamma = 90^\circ$.	
Volume	$2122.89(11)$ Å ³		
Z	4		
Density (calculated)	1.409 Mg/m ³		
Absorption coefficient	1.966 mm^{-1}		
F(000)	928		
Crystal size	$0.200 \times 0.170 \times 0.130$ mm ³		
Theta range for data collection	2.373 to 25.990°.		

Index ranges	-12 <= h <= 12, -39 <= k <= 35, -8 <= l <= 7
Reflections collected	11503
Independent reflections	4090 [R(int) = 0.0271]
Completeness to theta = 25.242°	98.6 %
Absorption correction	Mutli-scan
Max. and min. transmission	0.7456 and 0.5520
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	4090 / 1 / 262
Goodness-of-fit on F ²	1.034
Final R indices [I>2sigma(I)]	R1 = 0.0369, wR2 = 0.0832
R indices (all data)	R1 = 0.0552, wR2 = 0.0905
Absolute structure parameter	0.004(6)
Largest diff. peak and hole	0.496 and -0.532 e.Å ⁻³




Fig S3. X-ray structure of (5*R*,7*S*,8*R*)-4fa

Ellipsoids are drawn at the 30% probability level.

Crystal data and structure refinement for CCDC 1914518


(CCDC 1914518 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html.)

Table S3. Crystal data and structure refinement for (5*R*,7*S*,8*R*)-4fa.


Identification code	(5 <i>R</i> ,7 <i>S</i> ,8 <i>R</i>)-4fa
Empirical formula	C ₂₀ H ₂₄ BrN ₃ O ₄

Formula weight	450.33
Temperature	193(2) K
Wavelength	0.71073 Å
Crystal system	Orthorhombic
Space group	P 21 21 21
Unit cell dimensions	a = 6.4829(2) Å b = 12.2525(3) Å c = 26.9553(7) Å
	α= 90°. β= 90°. γ = 90°.
Volume	2141.11(10) Å ³
Z	4
Density (calculated)	1.397 Mg/m ³
Absorption coefficient	1.949 mm ⁻¹
F(000)	928
Crystal size	0.170 x 0.140 x 0.100 mm ³
Theta range for data collection	3.023 to 25.994°.
Index ranges	-7<=h<=7, -15<=k<=13, -33<=l<=28
Reflections collected	10450
Independent reflections	4108 [R(int) = 0.0299]
Completeness to theta = 25.242°	99.1 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.7456 and 0.3565
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	4108 / 1 / 262
Goodness-of-fit on F ²	1.042
Final R indices [I>2sigma(I)]	R1 = 0.0322, wR2 = 0.0731
R indices (all data)	R1 = 0.0389, wR2 = 0.0760
Absolute structure parameter	0.021(6)
Largest diff. peak and hole	0.541 and -0.487 e.Å ⁻³



Chiral HPLC Chromatograms




#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	10.05000	1029.96	27807.20	49.4381
2	16.13667	760.49	28439.24	50.5619





#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	10.39667	39.03	886.00	1.1011
2	16.03000	1612.69	79577.32	98.8989




#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	9.98750	878.14	22126.60	48.4710
2	17.37833	570.14	23522.51	51.5290






#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	10.15333	31.54	711.39	1.5740
2	17.20750	991.40	44484.49	98.4260








#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	8.63667	1406.54	31639.78	46.4025
2	16.72500	788.32	36545.69	53.5975




#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	8.63083	11.46	287.23	0.5931
2	15.90750	1032.13	48141.43	99.4069
















#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	10.80167	1191.65	32962.23	50.7590
2	18.03833	788.28	31976.44	49.2410








#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	10.98917	4.40	95.42	0.2286
2	17.96917	993.55	41640.82	99.7714

















#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	8.75000	752.58	19047.87	49.5488
2	11.24667	702.45	19394.81	50.4512




#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	9.55667	55.01	1313.01	2.3403
2	11.73667	1441.24	54791.27	97.6597














#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	9.072	1472555	37536555	47.808
2	16.621	764461	40978638	52.192









#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	9.347	38359	662721	1.085
2	16.262	997112	60445147	98.915

































































#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	14.36417	361.40	11798.68	48.9093
2	15.72083	329.09	12324.90	51.0907









#	Ret Time (min)	Height (mV)	Area (mV.sec)	Area (%)
1	14.22250	693.28	26633.60	98.2623
2	15.82000	13.76	471.01	1.7377























¹H NMR and ¹³C NMR spectra


¹H NMR spectrum of compound 3aa (CDCl₃)




¹³C NMR spectrum of compound 3aa (CDCl₃)




¹H NMR spectrum of compound **3ba** (CDCl_3)




¹³C NMR spectrum of compound **3ba** (CDCl_3)





¹H NMR spectrum of compound **3ca** (CDCl_3)





¹³C NMR spectrum of compound **3ca** (CDCl_3)




¹H NMR spectrum of compound **3da** (CDCl_3)




¹³C NMR spectrum of compound **3da** (CDCl_3)




¹H NMR spectrum of compound **3ea** (CDCl_3)




¹³C NMR spectrum of compound **3ea** (CDCl_3)




¹H NMR spectrum of compound **3fa** (CDCl_3)




¹³C NMR spectrum of compound **3fa** (CDCl_3)





¹H NMR spectrum of compound **3ga** (CDCl_3)





¹³C NMR spectrum of compound **3ga** (CDCl_3)




¹H NMR spectrum of compound **3ha** (CDCl_3)




¹³C NMR spectrum of compound **3ha** (CDCl_3)




¹H NMR spectrum of compound **3ia** (CDCl_3)




¹³C NMR spectrum of compound **3ia** (CDCl_3)




¹H NMR spectrum of compound **3ja** (CDCl_3)




¹³C NMR spectrum of compound **3ja** (CDCl_3)




¹H NMR spectrum of compound **3ka** (CDCl_3)




¹³C NMR spectrum of compound **3ka** (CDCl_3)





¹H NMR spectrum of compound **3la** (CDCl_3)





¹³C NMR spectrum of compound **3la** (CDCl_3)




¹H NMR spectrum of compound **3ma** (CDCl_3)




¹³C NMR spectrum of compound **3ma** (CDCl_3)




¹H NMR spectrum of compound **3na** (CDCl_3)




¹³C NMR spectrum of compound **3na** (CDCl_3)




¹H NMR spectrum of compound **3oa** (CDCl_3)




¹³C NMR spectrum of compound **3oa** (CDCl_3)




¹H NMR spectrum of compound **3pa** (CDCl_3)




¹³C NMR spectrum of compound **3pa** (CDCl_3)




¹H NMR spectrum of compound **3qa** (CDCl_3)




¹³C NMR spectrum of compound **3qa** (CDCl_3)




¹H NMR spectrum of compound **3ab** (CDCl_3)




¹³C NMR spectrum of compound **3ab** (CDCl_3)




¹H NMR spectrum of compound **3ac** (CDCl_3)




¹³C NMR spectrum of compound **3ac** (CDCl_3)




¹H NMR spectrum of compound **3ad** (CDCl_3)




¹³C NMR spectrum of compound **3ad** (CDCl_3)




¹H NMR spectrum of compound **3ae** (CDCl_3)




¹³C NMR spectrum of compound **3ae** (CDCl_3)




¹H NMR spectrum of compound **3af** (CDCl_3)




¹³C NMR spectrum of compound **3af** (CDCl_3)




¹H NMR spectrum of compound **3ag** (CDCl_3)




¹³C NMR spectrum of compound **3ag** (CDCl_3)




¹H NMR spectrum of compound **3ah** (CDCl₃)




¹³C NMR spectrum of compound **3ah** (CDCl_3)




¹H NMR spectrum of compound **3ai** (CDCl_3)




¹³C NMR spectrum of compound **3ai** (CDCl_3)




¹H NMR spectrum of compound **4aa** (CDCl_3)




¹³C NMR spectrum of compound **4aa** (CDCl_3)




¹H NMR spectrum of compound **4da** (CDCl_3)




¹³C NMR spectrum of compound **4da** (CDCl_3)




¹H NMR spectrum of compound **4fa** (CDCl_3)




¹³C NMR spectrum of compound **4fa** (CDCl_3)




¹H NMR spectrum of compound **4ia** (CDCl_3)




¹³C NMR spectrum of compound **4ia** (CDCl_3)




¹H NMR spectrum of compound **4oa** (CDCl_3)




¹³C NMR spectrum of compound **4oa** (CDCl_3)




¹H NMR spectrum of compound **4ab** (CDCl_3)




¹³C NMR spectrum of compound **4ab** (CDCl_3)




¹H NMR spectrum of compound **4ae** (CDCl_3)




¹³C NMR spectrum of compound **4ae** (CDCl_3)




¹H NMR spectrum of compound 5 (CDCl₃)



¹³C NMR spectrum of compound 5 (CDCl₃)



¹H NMR spectrum of compound **6** (CDCl_3)



¹³C NMR spectrum of compound **6** (CDCl_3)

